ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2465

Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study

Leah Ellingwood1, Orit Schieir2, Susan J. Bartlett3, Louis Bessette4, Carol A Hitchon5, Gilles Boire6, Glen Hazlewood7, Edward C. Keystone8, Diane Tin9, Carter Thorne10, Vivian P. Bykerk11 and Janet E. Pope12, 1Department of Internal Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 3Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumatology, Laval University, Québec, QC, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 7Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, 8University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Department of Medicine, University of Western Ontario, London, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Palindromic rheumatism (PR) (transient acute attacks of articular and/or periarticular inflammation) may progress to rheumatoid arthritis (RA). How often early RA (ERA) patients report joint symptoms that come and go prior to diagnosis and how RA presentation may differ in this patient subset is uncharacterized. This study compared ERA patients who did versus did not report a history of transient episodes of joint inflammation preceding RA diagnosis.
Methods: Data were from patients with early classifiable or suspected RA according to their rheumatologist (symptoms <1 year; 83% met 2010 ACR/EULAR criteria) enrolled in the Canadian Early ArThritis CoHort (CATCH) in 2017 to 2018 who completed a new baseline questionnaire on prior inflammatory joint symptoms that “come and go”. Chi-square and t-tests were used to compare baseline sociodemographic and RA characteristics in ERA patients with versus without a reported history of prior palindromic symptoms. Simple, and multivariable logistic regression with backward selection (p<0.1) were used to identify age and sex-adjusted predictors of palindromic symptoms among baseline ERA characteristics.

Results: 154 ERA patients were included; 66% were female and mean (sd) age was 54 (15) years. 83 (54%) patients reported having any previous joint pain and swelling prior to current episode; 65 (42%) endorsed prior episodic joint pain and swelling, of whom 31 (48%) reported transient joint symptoms for over six months. Patients reporting previous palindromic symptoms were more often female, RF positive, ACPA positive, had more comorbidities, and lower CRP, swollen joints, and baseline DAS28 (p<0.05). Univariate predictors of palindromic symptoms included female sex, RF positivity, higher income, comorbid OA, back/spine problems, and depression, higher rheumatic disease comorbidity index, and lower swollen joint count, CRP, DAS28, and physician global assessment of disease activity (p<0.1). In multivariable regression, RF positivity, depression, and higher income remained significant predictors of prior palindromic symptoms (p<0.05). Smoking was potentially associated with an average 3-fold increase in prior palindromic symptoms, though the relationship was not statistically significant in adjusted models (Table 1).

Conclusion:  ERA patients commonly self-reported experiencing transient episodes of inflammatory arthritis prior to being diagnosed with RA; however, whether these symptoms were actual PR cannot be confirmed. ERA patients who endorsed having joint symptoms that come and go prior to RA diagnosis were more likely RF positive with higher income and more comorbidities at ERA cohort entry, but median time to RA onset was not different.

 


Disclosure: L. Ellingwood, None; O. Schieir, None; S. J. Bartlett, UCB, Inc., 5,Lilly, 5,Pfizer, Inc., 5,Novartis, 5; L. Bessette, Amgen Inc., 2, 5, 8,Bristol-Myers Squibb, 2, 5, 8,Janssen, 2, 5, 8,Roche, 2, 5, 8,UCB, Inc., 2, 5, 8,AbbVie Inc., 2, 5, 8,Pfizer, Inc., 2, 5, 8,Merck & Co., 2, 5, 8,Celgene Corporation, 2, 5, 8,Sanofi, 2, 5, 8,Eli Lilly and Co., 2, 5, 8,Novartis, 2, 5, 8; C. A. Hitchon, Pfizer, Inc., 2,UCB, Inc., 2; G. Boire, Merck & Co., 8, 9,BMS, 8, 9,Pfizer, Inc., 8, 9,Amgen Inc., 9,AbbVie Inc., 9,Novartis, 9,Eli Lilly and Co., 9,Janssen, 9; G. Hazlewood, None; E. C. Keystone, Amgen Inc., 2, 5, 8,Bristol-Myers Squibb, 2,F. Hoffmann-La Roche Inc, 2,Janssen, 2,Lilly Pharmaceuticals, 2,Pfizer Pharmaceuticals, 2,Sanofi-Aventis, 2,AstraZeneca, 5,Biotest, 5,Bristol-Myers Squibb, 5,Crescendo Bioscience, 5,F. Hoffmann-La Roche Inc, 5,Genentech Inc, 5,Janssen Inc, 5,Lilly Pharmaceuticals, 5,Merck & Co., 5, 8,Pfizer Pharmaceuticals, 5,UCB, Inc., 5,Bristol-Myers Squibb, 8,F. Hoffmann-La Roche Inc, 8,Janssen Inc, 8,Pfizer Pharmaceuticals, 8,Sanofi Genzyme, 8,UCB, Inc., 8; D. Tin, None; C. Thorne, AbbVie Inc., 5, 9,Amgen Inc., 9,Celgene Corporation, 9,Centocor, 5,Janssen, 5,Lilly, 5, 9,Medexus/Medac, 5, 8, 9,Merck & Co., 9,Novartis, 9,Pfizer, Inc., 5, 9,Senofi, 9; V. P. Bykerk, Amgen Inc., 5,Pfizer, Inc., 5,UCB, Inc., 5,Bristol-Myers Squibb, 5,Sanofi-Genzyme/Regeneron, 5; J. E. Pope, Amgen Inc., 5, 9,Pfizer, Inc., 5, 9,UCB, Inc., 5, 9,AbbVie Inc., 5,Bristol-Myers Squibb, 5, 9,Actelion, 5,Eli Lilly and Co., 5,Merck & Co., 5, 9,Bayer, 5, 9,Roche, 5, 9,Novartis, 5,Sanofi, 5,Celtrion, 5,Seagen, 9,Genzyme, 5.

To cite this abstract in AMA style:

Ellingwood L, Schieir O, Bartlett SJ, Bessette L, Hitchon CA, Boire G, Hazlewood G, Keystone EC, Tin D, Thorne C, Bykerk VP, Pope JE. Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/characterizing-palindromic-symptoms-in-early-rheumatoid-arthritis-results-from-the-canadian-early-arthritis-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-palindromic-symptoms-in-early-rheumatoid-arthritis-results-from-the-canadian-early-arthritis-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology